Author ORCID Identifier

https://orcid.org/0000-0001-7665-026X : Abhinandan Banerjee

https://orcid.org/0000-0002-7502-7780 : John J. Hayward

https://orcid.org/0000-0002-4780-4968 : John F. Trant

Document Type

Article

Publication Date

2-10-2023

Publication Title

Organic & Biomolecular Chemistry

Volume

2023

Issue

21

First Page

3715

Last Page

3732

Abstract

Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two “major cannabinoids”. However, their incorporation into clinical and nutraceutical preparations is challenging, owing to their limited bioavailability, low water solubility, and variable pharmacokinetic profiles. Understanding the organic chemistry of the major cannabinoids provides us with potential avenues to overcome these issues through derivatization. The resulting labile pro-drugs offer ready cannabinoid release in vivo, have augmented bioavailability, or demonstrate interesting pharmacological properties in their own right. This review identifies and discusses a subset of these advanced derivatization strategies for the major cannabinoids, where the starting material is the pure phytocannabinoid itself, and the final product either a cannabinoid pro-drug, or a novel pharmacoactive material.

DOI

10.1039/D3OB00068K

ISSN

1477-0520

Share

COinS